17:38 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III...
18:42 , Oct 17, 2018 |  BC Extra  |  Clinical News

Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III...
20:14 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at bedtime met the...
18:43 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's lemborexant meets in Phase III for insomnia

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase III SUNRISE 1 trial in about 1,000 patients ages 55 and older with insomnia showing that oral lemborexant (E2006)...
00:18 , May 19, 2017 |  BC Week In Review  |  Clinical News

Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low- and high-dose lorediplon significantly reduced mean Wake After...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Rat studies suggest GRIA antagonists or GABA A receptor agonists could help treat L-DOPA-induced dyskinesia in PD. In a rat model of L-DOPA-induced dyskinesia in PD, infusion into the primary motor...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Lorediplon: Completed Phase IIa enrollment

Ergomed completed enrollment of >=130 adult insomniacs in a double-blind, placebo-controlled, crossover, international Phase IIa trial comparing 5 and 10 mg oral lorediplon vs. zolpidem. Ferrer is conducting the trial in collaboration with CRO Ergomed...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Lorediplon: Phase IIa started

Ferrer began a double-blind, placebo-controlled, crossover, international Phase IIa trial to compare 5 and 10 mg oral Lorediplon vs. zolpidem in about 130 adult insomniacs. Ferrer is conducting the trial in collaboration with CRO Ergomed...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Sellas, Catalent Pharma deal

Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) using Catalent’s OSDrC OptiDose drug delivery technology. Catalent will develop the formulation and manufacture and distribute...